Clinical Trial

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 22, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell non-Hodgkin lymphoma and B-cell lymphocytic leukemia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-12.
Trial Details
NCT Number NCT06037018
Lead Sponsor CytoCares Inc
Conditions Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
Enrollment 44 participants
Start Date 2023-08-07
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-22